Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | Deglutition Disorders, Digestive System Diseases, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease | Recruiting | Phase 3 | 2026-10-07 | NCT07752407 | |
| A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring | Heartburn, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive | Recruiting | Not stated | 2026-09-18 | NCT06660342 | |
| Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study) | Barrett esophagus, Digestive System Diseases, digestive system disorder, esophageal disorder, neoplasm, precancerous condition | Not yet recruiting | Phase 4 | 2026-08-26 | NCT07788742 | |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-06-29 | NCT06851559 |